Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Study provides better understanding of how therapeutic resistance develops in lung cancer

Study provides better understanding of how therapeutic resistance develops in lung cancer

Importance of Numb-associated kinases in SARS-CoV-2 infection

Importance of Numb-associated kinases in SARS-CoV-2 infection

New approach could be a useful tool in the fight against cancer drug resistance

New approach could be a useful tool in the fight against cancer drug resistance

Scientists discover new treatment target for osteoarthritis-like knee cartilage degeneration

Scientists discover new treatment target for osteoarthritis-like knee cartilage degeneration

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors

Turning autoimmunity drugs into anti-cancer treatments

Turning autoimmunity drugs into anti-cancer treatments

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

AI may help predict tumor sensitivity to systemic cancer therapies

AI may help predict tumor sensitivity to systemic cancer therapies

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Study: Cancer stem-like cells are maintained by MTHFD2 mitochondrial metabolic enzyme

Study: Cancer stem-like cells are maintained by MTHFD2 mitochondrial metabolic enzyme

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Study suggests new target to treat prostate cancer

Study suggests new target to treat prostate cancer

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Targeted therapy appears to be more effective in preventing lung cancer recurrence

Targeted therapy appears to be more effective in preventing lung cancer recurrence

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

Penn studies provide new understanding of lung cancer progression and prevention

Penn studies provide new understanding of lung cancer progression and prevention